Skip to content

Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer

Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02861196
Enrollment
59
Registered
2016-08-10
Start date
2015-09-30
Completion date
2018-09-30
Last updated
2020-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Brief summary

This research aims to explore the therapeutic effect of neoadjuvant chemotherapy in muscular invasive bladder cancer of T2-4aN0M0, and the survival effect of combined-modality treatment model,then to clarify the probability of bladder preservation, corresponding cancer specific survival, and the quality of life.

Interventions

PROCEDUREIntensity modulated radiation therapy, Radical cystectomy

Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. bladder urothelium carcinoma 2. cT2-4aN0M0 3. life expectancy≥1 year 4. ECOG PS 0-1 5. have no previously received radiotherapy or chemotherapy 6. have no major organ dysfunction 7. have been provided informed written consent

Exclusion criteria

1. extensive carcinoma in situ or ureter invaded 2. distant metastasis at primary diagnosis or lymphatic metastasis according to clinical diagnosis 3. have severe major organ dysfunction 4. cannot finish treatments because of other severe diseases or life expectance≤6 months 5. exist other malignant tumors 6. have severe coagulation disorders 7. no other trails participated in 4 weeks

Design outcomes

Primary

MeasureTime frameDescription
bladder preservation rate3 yearsbladder preservation rate

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026